Alterations in the p16INK4a/Cyclin D1/RB pathway in gastrointestinal tract endocrine tumors

被引：16

作者：

Li, Anna Fen-Yau ^{[1
,2
]}

Li, Alice Chia-Heng ^{[3
]}

Tsay, Shyh-How ^{[1
]}

Li, Wing-Yin ^{[1
]}

Liang, Wen-Yih ^{[1
]}

Chen, Jeou-Yuan ^{[4
]}

机构：

[1] Taipei Vet Gen Hosp, Dept Pathol, Taipei, Taiwan

[2] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan

[3] Vivian Webb Sch, Claremont, CA USA

[4] Acad Sinica, IBMS, Taipei 115, Taiwan

来源：

AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2008年 / 130卷 / 04期

关键词：

endocrine carcinoma; carcinoid; gastrointestinal tract; p16(INK4a); cyclin D1; retinoblastoma protein; pRB;

D O I：

10.1309/TLLVXK9HVA89CHPE

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

A series of 76 cases of gastrointestinal tract endocrine tumors, including 21 poorly differentiated endocrine carcinomas (PDECs, small cell carcinomas) and 55 well-differentiated endocrine neoplasms (WDENs, carcinoids), 18 metastatic and 3 7 nonmetastatic rectal carcinoids, were examined by immunohistochemical analysis for p16(INK4a), cyclin DI, and retinoblastoma protein (pPB) expression. Overexpression of p16(INK4a) was noted in 16 (76%) of the PDECs and none of the WDENs (P < .0001). Loss of pRB expression was demonstrated in 14 (67%) of the PDECs and 17 (31%) of the WDENs (P =. 004). Overexpression of cyclin D1 was noted in 49 (89%) of the WDENs and 3 (14%) of the PDECs (P < .0001). Loss of pRB expression was noted in 11 (61%) of 18 metastatic WDENs and only 6 (16%) of 37 nonmetastatic WDENs (P = .001). The p16(INK4a)/cyclin D1/pRB pathway was altered in gastrointestinal tract endocrine tumors, and the loss of expression of pRB may be helpful in identifying patients at high risk of metastasis in rectal WDENs.

引用

页码：535 / 542

页数：8

共 36 条

[1] Endocrine tumors of the gastrointestinal tract and pancreas:grading, tumor size and proliferation index do not predict malignant behavior [J].

Alexiev, Borislav A. ;

Drachenberg, Cinthia B. ;

Papadimitriou, John C. .

DIAGNOSTIC PATHOLOGY, 2007, 2 (1)

[2] Neuroendocrine tumours [J].

Barakat, MT ;

Meeran, K ;

Bloom, SR .

[3] The P16/cyclin D1/Rb pathway in neuroendocrine tumors of the lung [J].

Beasley, MB ;

Lantuejoul, S ;

Abbondanzo, S ;

Chu, WS ;

Hasleton, P ;

Travis, WD ;

Brambilla, E .

HUMAN PATHOLOGY, 2003, 34 (02) :136-142

[4] Neuroendocrine carcinomas of the colon and rectum [J].

Bernick, PE ;

Klimstra, DS ;

Shia, J ;

Minsky, B ;

Saltz, L ;

Shi, W ;

Thaler, H ;

Guillem, J ;

Paty, P ;

Cohen, AM ;

Wong, WD .

DISEASES OF THE COLON & RECTUM, 2004, 47 (02) :163-169

[5] Small-cell carcinomas of the gastrointestinal tract: A review [J].

Brenner, B ;

Tang, LH ;

Klimstra, DS ;

Kelsen, DP .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2730-2739

[6] Small-cell neuroendocrine carcinoma displays unique profiles of tumor-suppressor gene loss in relationship to the primary site of formation [J].

Dacic, S ;

Finkelstein, SD ;

Baksh, FK ;

Swalsky, PA ;

Barnes, LE ;

Yousem, SA .

HUMAN PATHOLOGY, 2002, 33 (09) :927-932

[7] Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha [J].

Esuvaranathan, Kesavan ;

Chiong, Edmund ;

Thamboo, Thomas Paulraj ;

Chan, Yiong Huak ;

Kamaraj, Revathi ;

Mahendran, Ratha ;

Teh, Ming .

CANCER, 2007, 109 (06) :1097-1105

[8] Abnormal expression of pRb, p16, and cyclin D1 in gastric adenocarcinoma and its lymph node metastases: Relationship with pathological features and survival [J].

Feakins, RM ;

Nickols, CD ;

Bidd, H ;

Walton, SJ .

HUMAN PATHOLOGY, 2003, 34 (12) :1276-1282

[9] Quantitative expansion of structural genomic alterations in the spectrum of neuroendocrine lung carcinomas [J].

Gugger, M ;

Burckhardt, E ;

Kappeler, A ;

Hirsiger, H ;

Laissue, JA ;

Mazzucchelli, L .

JOURNAL OF PATHOLOGY, 2002, 196 (04) :408-415

[10]

Hamilton SR., 2000, WHO CLASSIFICATION T

← 1 2 3 4 →